ABUS vs RTX · P/E 5.4, rev $6.2M vs P/E 36, rev $88.60B
Arbutus Biopharma Corp (ABUS) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the ABUS and RTX stock pages for the full models.
Not investment advice.